FDA Approves First-in-Class Drug for Rare Blood Cancer

Patients battling a rare and stubborn blood cancer just gained a powerful new option after the FDA approved the first drug in its class to treat mantle cell lymphoma.

The daily pill offers hope for patients who've exhausted other treatments, with trial results showing responses lasting over a year.